Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine in Pediatric Cardiac Catheterization
NCT04258007Completed
- Sponsor
- Mansoura University
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in congenital heart disease (CHD) (2 arms), sponsored by Mansoura University. Primary endpoint: Reversal efficacy. Started Jan 2020; status: completed.
02
Drugs
Sugammadex
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT04258007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258007.